Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.84 |
| ▸ | PKM | P14618 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | POLB | P06746 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347059 | 0.93 | ALDH1A1 (0.97) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL2061369 | 0.92 | PKM (0.76) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL1024915 | 0.92 | ALDH1A1 (0.73) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL28137833 | 0.92 | ALDH1A1 (1.00) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL17007463 | 0.90 | ALDH1A1 (0.75) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL7647475 | 0.90 | ALDH1A1 (0.75) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL14256511 | 0.89 | PKM (0.72) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL31234627 | 0.89 | POLB (0.75) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL2062534 | 0.89 | POLB (0.75) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL29432508 | 0.89 | ALDH1A1 (0.73) | ALDH1A1PKMKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150342927-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9108916-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140303224-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, LLC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2664617-A1 | Method of making a 2,6-diaryl piperidine derivative | Genzyme Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2356093-B1 | Carbazole compounds and therapeutic uses of the compounds | INCURON LLC (RU) | 2013-01-09 | — | — | EP | disclosed |
| EP-1809613-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2007-07-25 | — | — | EP | disclosed |
| CN-1777423-A | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED INC (CA) | 2006-05-24 | — | — | CN | disclosed |
| WO-2006049764-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2006-05-11 | — | — | WO | disclosed |
| EP-1615633-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-01-18 | — | — | EP | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
| US-6716961-B2 | Chiral peptide nucleic acids with a N-aminoethyl-d-proline backbone | ISIS INNOVATION LIMITED (GB) | 2004-04-06 | — | — | US | disclosed |
| US-20030162699-A1 | Chiral peptide nucleic acids with a n-aminoethyl-d-proline backbone | ISIS INNOVATION LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6451918-B1 | LINKER THAT ALLOWS CLEAVAGE OF THE AMINE FROM THE SOLID SUPPORT UNDER MILD REACTION CONDITIONS WHILE STILL PROVIDING THE GREATEST DEGREE OF SYNTHETIC VERSATILITY | COELACANTH CORPORATION | 2002-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | ALDH1A1 633/4885PKM 2381/4885KMT2A 3680/4885 |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | ALDH1A1 3/4885PKM 2161/4885KMT2A 1667/4885 |
| US-20150342927-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | ALDH1A1 633/4885PKM 2381/4885KMT2A 3680/4885 |
| US-20030162699-A1 | Chiral peptide nucleic acids with a n-aminoethyl-d-proline backbone | POLL, HNRNPL, RNGTT | ALDH1A1 4356/4885PKM 1707/4885KMT2A 2081/4885 |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | MALT1, PAICS, BCL9 | ALDH1A1 633/4885PKM 2381/4885KMT2A 3680/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | ALDH1A1 290/4885PKM 4245/4885KMT2A 2901/4885 |
| US-20140303224-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | ALDH1A1 633/4885PKM 2381/4885KMT2A 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.